111 related articles for article (PubMed ID: 30872381)
1. Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Floc'h N; Ashton S; Ferguson D; Taylor P; Carnevalli LS; Hughes AM; Harris E; Hattersley M; Wen S; Curtis NJ; Pilling JE; Young LA; Maratea K; Pease EJ; Barry ST
Mol Cancer Ther; 2019 May; 18(5):909-919. PubMed ID: 30872381
[TBL] [Abstract][Full Text] [Related]
2. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
Ashton S; Song YH; Nolan J; Cadogan E; Murray J; Odedra R; Foster J; Hall PA; Low S; Taylor P; Ellston R; Polanska UM; Wilson J; Howes C; Smith A; Goodwin RJ; Swales JG; Strittmatter N; Takáts Z; Nilsson A; Andren P; Trueman D; Walker M; Reimer CL; Troiano G; Parsons D; De Witt D; Ashford M; Hrkach J; Zale S; Jewsbury PJ; Barry ST
Sci Transl Med; 2016 Feb; 8(325):325ra17. PubMed ID: 26865565
[TBL] [Abstract][Full Text] [Related]
4. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
6. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
[TBL] [Abstract][Full Text] [Related]
7. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Ramkumar K; Tanimoto A; Della Corte CM; Stewart CA; Wang Q; Shen L; Cardnell RJ; Wang J; Polanska UM; Andersen C; Saeh J; Pease JE; Travers J; Fabbri G; Gay CM; Urosevic J; Byers LA
Clin Cancer Res; 2023 Aug; 29(16):3237-3249. PubMed ID: 37289191
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
Zekri A; Ghaffari SH; Yaghmaie M; Estiar MA; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
Mol Neurobiol; 2016 Apr; 53(3):1808-1823. PubMed ID: 25752998
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia.
Alferez DG; Goodlad RA; Odedra R; Sini P; Crafter C; Ryan AJ; Wedge SR; Wright NA; Anderson E; Wilkinson RW
Int J Oncol; 2012 Oct; 41(4):1475-85. PubMed ID: 22858681
[TBL] [Abstract][Full Text] [Related]
10. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
11. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
Guo J; Anderson MG; Tapang P; Palma JP; Rodriguez LE; Niquette A; Li J; Bouska JJ; Wang G; Semizarov D; Albert DH; Donawho CK; Glaser KB; Shah OJ
Pharmacogenomics J; 2009 Apr; 9(2):90-102. PubMed ID: 19188929
[TBL] [Abstract][Full Text] [Related]
12. A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system.
Song YH; Shin E; Wang H; Nolan J; Low S; Parsons D; Zale S; Ashton S; Ashford M; Ali M; Thrasher D; Boylan N; Troiano G
J Control Release; 2016 May; 229():106-119. PubMed ID: 27001894
[TBL] [Abstract][Full Text] [Related]
13. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
14. Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
Zekri A; Mesbahi Y; Ghanizadeh-Vesali S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Anticancer Drugs; 2017 Sep; 28(8):841-851. PubMed ID: 28639950
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
16. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
Nair JS; de Stanchina E; Schwartz GK
Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
[TBL] [Abstract][Full Text] [Related]
17. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
[TBL] [Abstract][Full Text] [Related]
18. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
19. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]